Erratum to: Pain and Health-Related Quality of Life in Patients with Advanced Solid Tumours and Bone Metastases: Integrated Results from Three Randomized, Double-Blind Studies of Denosumab and Zoledronic Acid

Details

• Personal Author:
  Body, Jean-Jacques ; Braun, Ada ; Brown, Janet E. ; Chung, Karen ; Cleeland, Charles S. ; Damyanov, Danail ; Egerdie, Blair ; Fallowfield, Lesley J. ; Marx, Gavin ; Palazzo, Felipe G. ; Patrick, Donald L. ; Qian, Yi ; Stopeck, Alison ; von Moos, Roger
• Description:
  Purpose: This analysis evaluated patient-reported outcomes and analgesic use in patients with bone metastases from solid tumours across three comparative studies of denosumab and zoledronic acid. Methods: Pooled data were analysed from three identically designed double-blind phase III studies comparing subcutaneous denosumab 120 mg with intravenous zoledronic acid 4 mg monthly in patients with bone metastases from breast cancer (n = 2,046), castration-resistant prostate cancer (n = 1,901) or other solid tumours (n = 1,597). Pain severity, pain interference, health-related quality of life and analgesic use were quantified. Results: At baseline, approximately half of patients had no/mild pain (53 % [1,386/2,620] denosumab; 50 % [1,297/2,578] zoledronic acid). Denosumab delayed onset of moderate/severe pain by 1.8 months (median, 6.5 vs 4.7 months; hazard ratio, 0.83; 95 % CI, 0.76-0.92; p < 0.001; 17 % risk reduction) and clinically meaningful increases in overall pain interference by 2.6 months (median, 10.3 vs 7.7 months; hazard ratio, 0.83; 95 % CI, 0.75-0.92; p < 0.001; 17 % risk reduction) compared with zoledronic acid. Strong opioid use and worsening of health-related quality of life were less common with denosumab. Conclusions: Across three large studies of patients with advanced solid tumours and bone metastases, denosumab prevented progression of pain severity and pain interference more effectively than zoledronic acid. An erratum to this article can be found at https://doi.org/10.1007/s00520-014-2293-1. [Description provided by NIOSH]
• Subjects:
  Drug Therapy Neoplasms Occupational Health Safety
• Keywords:
  Author Keywords: Denosumab; Bone Metastases; Pain; Solid Tumours; Zoledronic Acid Cancer; Bone Disorders; Metastatic Disease; Quality Of Life; Medical Treatment; Drug Therapy;
• ISSN:
  0941-4355
• Document Type:
  Text
• Funding:
  Grant
• Genre:
  Journal Article
• Place as Subject:
  Arizona ; California ; OSHA Region 10 ; OSHA Region 9 ; Washington
• CIO:
  National Institute for Occupational Safety and Health (NIOSH)
• Topic:
  Workplace Safety & Health
• Location:
  North America
• Pages in Document:
  2 pdf pages
• Volume:
  22
• NIOSHTIC Number:
  nn:20057207
• Citation:
  Support Care Cancer 2013 Dec; 21(12):3497-3507
• Contact Point Address:
  Roger von Moos, Kantonsspital Graubünden, Loëstrasse 170, 7000 Chur, Switzerland
• Email:
  Roger.vonmoos@ksgr.ch
• Federal Fiscal Year:
  2014
• Performing Organization:
  University of Washington
• Peer Reviewed:
  True
• Start Date:
  20050701
• Source Full Name:
  Supportive Care in Cancer
• End Date:
  20250630
• Collection(s):
  National Institute for Occupational Safety and Health
• Main Document Checksum:
  urn:sha-512:81dc35899bedfd26728df22b82fa40bea7fc8542cd5e4170cf497ec1e891259f05af59e0bd20931a72bb90aeca3c53702ee676597e8b2c1cb3d2b13274c8ea4a
• Download URL:
  https://stacks.cdc.gov/view/cdc/231600/cdc_231600_DS1.pdf
• File Type:
  [PDF - 132.12 KB ]